Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | PGR | P06401 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11874257 | 1.00 | ESR1 (0.57) | ESR1CHRM2SLC6A2SLC6A4CYP2C19 | |
| SCHEMBL11866439 | 0.81 | SLC6A4 (0.61) | ESR1CHRM2SLC6A2SLC6A4CYP2C19 | |
| SCHEMBL2507306 | 0.80 | CYP19A1 (0.40) | ESR1CHRM2SLC6A2SLC6A4CYP2C19 | |
| SCHEMBL30361235 | 0.80 | ESR1 (0.57) | ESR1CHRM2SLC6A2SLC6A4CYP2C19 | |
| SCHEMBL19608861 | 0.78 | CYP19A1 (0.66) | ESR1SLC6A4CYP2C19ALDH1A1PGR | |
| SCHEMBL7861153 | 0.78 | CYP19A1 (0.66) | ESR1CHRM2SLC6A2SLC6A4CYP2C19 | |
| SCHEMBL922877 | 0.78 | CYP19A1 (0.66) | ESR1SLC6A4CYP2C19ALDH1A1PGR | |
| SCHEMBL3775778 | 0.78 | ESR1 (0.55) | ESR1CHRM2SLC6A2SLC6A4CYP2C19 | |
| SCHEMBL13216466 | 0.78 | CYP19A1 (0.66) | ESR1SLC6A4CYP2C19ALDH1A1PGR | |
| SCHEMBL11977689 | 0.78 | CYP19A1 (0.66) | ESR1SLC6A4CYP2C19ALDH1A1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113045616-B | Preparation method of 6-dehydronandrolone acetate | 湖北共同药业股份有限公司 | 2022-06-14 | — | — | CN | claimed |
| US-6117429-A | ANTIDIHYDROTESTOSTERONE ZINC COMPOUND | WEIDER NUTRITION INTERNATIONAL, INC (US) | 2000-09-12 | — | — | US | claimed |
| US-6011027-A | Use of 19-nor-4-androstenediol to increase 19-nortestosterone levels in humans | LPJ RESEARCH, INC. (US) | 2000-01-04 | — | — | US | claimed |
| US-20240165245-A1 | MULTIVALENT PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2024-05-23 | — | — | US | disclosed |
| US-11766480-B2 | Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same | NEW YORK UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| CN-115448969-A | Refining method of desogestrel | 上海格苓凯生物科技有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-113045616-B | Preparation method of 6-dehydronandrolone acetate | 湖北共同药业股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3955887-A1 | DELIVERY AND RETENTION OF ACTIVE AGENTS WITHIN THE SKIN | Fount Bio, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3808348-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3025714-B9 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3025714-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-8084446-B2 | Use of DHEA derivatives for enhancing physical performance | INTELLECTUAL WELLNESS, LLC | 2011-12-27 | — | — | US | disclosed |
| US-20110245216-A1 | USE OF DHEA DERIVATIVES FOR ENHANCING PHYSICAL PERFORMANCE | PROPRIETARY WELLNESS LLC (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2200611-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen Idec MA, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7655756-B2 | Crystallized structure of estrogen related receptor gamma in complex with bisphenol A | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2009038684-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20060270836-A1 | Peptide fragment comprising the Ligand Binding Domain (LBD) of ERR gamma in complex with Bisphenol A; used to design or select compounds which have an effect on ERR gamma activity; drug screening | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC | 2006-11-30 | — | — | US | disclosed |
| US-20060241093-A1 | Use of DHEA derivatives for enhancing physical performance | INTELLECTUAL WELLNESS, LLC | 2006-10-26 | — | — | US | disclosed |
| US-6011027-A | Use of 19-nor-4-androstenediol to increase 19-nortestosterone levels in humans | LPJ RESEARCH, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-3959322-A | Synthesis of 13-alkyl-gon-4-ones | Smith, Herchel (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241093-A1 | Use of DHEA derivatives for enhancing physical performance | SHBG, HSD11B1, HSD17B11 | ESR1 1085/4885CHRM2 4376/4885SLC6A2 1559/4885 |
| US-20240165245-A1 | MULTIVALENT PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | AR, SHBG, KLK3 | ESR1 476/4885CHRM2 3825/4885SLC6A2 4654/4885 |
| US-20110245216-A1 | USE OF DHEA DERIVATIVES FOR ENHANCING PHYSICAL PERFORMANCE | SHBG, HSD11B1, HSD17B11 | ESR1 1085/4885CHRM2 4376/4885SLC6A2 1559/4885 |
| US-11766480-B2 | Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same | AR, SHBG, KLK3 | ESR1 476/4885CHRM2 3825/4885SLC6A2 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.